Company profile
High-resolution telomere analysis | TeloNostiX
TeloNostiX platform technologies have applications for the prognosis and prediction of response to treatment for cancer patients and risk-adapted clinical trials.
Financial period: 1 Nov 2023 to 31 Oct 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQ0MTI2ODEyOWFkaXF6a2N4
Published 29 Oct 2024 01:48
AD01 | Transaction MzQzOTAzMjk1OGFkaXF6a2N4
Published 10 Oct 2024 09:59
Company registered at Companies House
1 Feb 2018 to 31 Jan 2019
A case study for Innovate UK's Precision Medicine Catapult (PMC) (whose activities now fall under the Medicines Discvovery Catapult (MDC)), TeloNostiX Ltd's prognostic test for Chronic Lymphocytic Leukaemia (CLL) through Single Telomere Length Analysis (STELA) helps address two significant global healthcare challenges: 1) patient stratification and 2) pre...
